Heparin concentration is critical for cell culture with human platelet lysate

Cytotherapy

Volumn 15, Issue 9, 2013, Pages 1174-1181

  Hemeda, Hatim ^a   Kalz, Jana ^a   Walenda, Gudrun ^a   Lohmann, Michael ^a   Wagner, Wolfgang ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Differentiation; Fetal bovine serum; Fibroblasts; Human platelet lysate; Mesenchymal stromal cells; Platelet lysate gel; Proliferation; Serum

Indexed keywords

BENZYL ALCOHOL; ENOXAPARIN; HEPARIN;

ADIPOSE TISSUE CELL; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL EXPANSION; CELL STRUCTURE; CELL VIABILITY; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DOSE RESPONSE; FIBROBLAST; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; IN VITRO STUDY; MESENCHYMAL STROMA CELL; OSTEOBLAST; PRIORITY JOURNAL;

BOVINAE;

DIFFERENTIATION; FETAL BOVINE SERUM; FIBROBLASTS; HUMAN PLATELET LYSATE; MESENCHYMAL STROMAL CELLS; PLATELET LYSATE GEL; PROLIFERATION; SERUM;

ADIPOGENESIS; BLOOD PLATELETS; CELL DIFFERENTIATION; CELL EXTRACTS; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CULTURE MEDIA; HEPARIN; HUMANS; IMMUNOPHENOTYPING; MESENCHYMAL STROMAL CELLS; OSTEOGENESIS;

EID: 84881101817     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2013.05.006     Document Type: Article

References (48)

1. Salem H.K., Thiemermann C. Mesenchymal stromal cells: current understanding and clinical status. Stem Cells 2010, 28:585-596.
2. Sensebe L., Krampera M., Schrezenmeier H., Bourin P., Giordano R. Mesenchymal stem cells for clinical application. Vox Sang 2009, 98:93-107.
3. Jung S., Sen A., Rosenberg L., Behie L.A. Identification of growth and attachment factors for the serum-free isolation and expansion of human mesenchymal stromal cells. Cytotherapy 2010, 12:637-657.
4. Doucet C., Ernou I., Zhang Y., Llense J.R., Begot L., Holy X., et al. Platelet lysates promote mesenchymal stem cell expansion: a safety substitute for animal serum in cell-based therapy applications. JCell Physiol 2005, 205:228-236.
5. Schallmoser K., Bartmann C., Rohde E., Reinisch A., Kashofer K., Stadelmeyer E., et al. Human platelet lysate can replace fetal bovine serum for clinical-scale expansion of functional mesenchymal stromal cells. Transfusion 2007, 47:1436-1446.
6. Fekete N., Gadelorge M., Furst D., Maurer C., Dausend J., Fleury-Cappellesso S., et al. Platelet lysate from whole blood-derived pooled platelet concentrates and apheresis-derived platelet concentrates for the isolation and expansion of human bone marrow mesenchymal stromal cells: production process, content and identification of active components. Cytotherapy 2012, 14:540-554.
7. Fekete N., Rojewski M.T., Furst D., Kreja L., Ignatius A., Dausend J., et al. GMP-compliant isolation and large-scale expansion of bone marrow-derived MSC. PLoS One 2012, 7:e43255.
8. Kinzebach S., Bieback K. Expansion of mesenchymal stem/stromal cells under xenogenic-free culture conditions. Adv Biochem Eng Biotechnol 2013, 129:33-57.
9. Capelli C., Domenghini M., Borleri G., Bellavita P., Poma R., Carobbio A., et al. Human platelet lysate allows expansion and clinical grade production of mesenchymal stromal cells from small samples of bone marrow aspirates or marrow filter washouts. Bone Marrow Transplant 2007, 40:785-791.
10. Avanzini M.A., Bernardo M.E., Cometa A.M., Perotti C., Zaffaroni N., Novara F., et al. Generation of mesenchymal stromal cells in the presence of platelet lysate: a phenotypic and functional comparison of umbilical cord blood- and bone marrow-derived progenitors. Haematologica 2009, 94:1649-1660.
11. Holzwarth C., Vaegler M., Gieseke F., Pfister S.M., Handgretinger R., Kerst G., et al. Low physiologic oxygen tensions reduce proliferation and differentiation of human multipotent mesenchymal stromal cells. BMC Cell Biol 2010, 11:11.
12. Muller I., Kordowich S., Holzwarth C., Spano C., Isensee G., Staiber A., et al. Animal serum-free culture conditions for isolation and expansion of multipotent mesenchymal stromal cells from human BM. Cytotherapy 2006, 8:437-444.
13. Lohmann M., Walenda G., Hemeda H., Joussen S., Drescher W., Jockenhoevel S., et al. Donor age of human platelet lysate affects proliferation and differentiation of mesenchymal stem cells. PLoS One 2012, 7:e37839.
14. Cholewa D., Stiehl T., Schellenberg A., Bokermann G., Joussen S., Koch C., et al. Expansion of adipose mesenchymal stromal cells is affected by human platelet lysate and plating density. Cell Transplant 2011, 20:1409-1922.
15. Bieback K., Hecker A., Kocaomer A., Lannert H., Schallmoser K., Strunk D., et al. Human alternatives to fetal bovine serum for the expansion of mesenchymal stromal cells from bone marrow. Stem Cells 2009, 27:2331-2341.
16. Horn P., Bokermann G., Cholewa D., Bork S., Walenda T., Koch C., et al. Comparison of individual platelet lysates for isolation of human mesenchymal stromal cells. Cytotherapy 2010, 12:888-898.
17. Schallmoser K., Strunk D. Preparation of pooled human platelet lysate (pHPL) as an efficient supplement for animal serum-free human stem cell cultures. JVis Exp 2009, 32:1-4.
18. Walenda G., Hemeda H., Schneider R.K., Merkel R., Hoffmann B., Wagner W. Human platelet lysate gel provides a novel 3D-matrix for enhanced culture expansion of mesenchymal stromal cells. Tissue Eng Part C Methods 2012, 18:924-934.
19. Andersen J.C. Advances in anticoagulation therapy: the role of selective inhibitors of factor Xa and thrombin in thromboprophylaxis after major orthopedic surgery. Semin Thromb Hemost 2004, 30:609-618.
20. Hofmann T. Clinical application of enoxaparin. Expert Rev Cardiovasc Ther 2004, 2:321-337.
21. Simonneau G., Laporte S., Mismetti P., Derlon A., Samii K., Samama C.M., et al. Arandomized study comparing the efficacy and safety of nadroparin 2850 IU (0.3 mL) vs. enoxaparin 4000 IU (40 mg) in the prevention of venous thromboembolism after colorectal surgery for cancer. JThromb Haemost 2006, 4:1693-1700.
22. Marincola F.M., Drucker B.J., Siao D.Y., Holder W.D. Inhibition of activation of lymphokine-activated killer cells in vitro by the heparin preservative benzyl alcohol. Lancet 1987, 2:399.
23. Walker C.P., Royston D. Thrombin generation and its inhibition: a review of the scientific basis and mechanism of action of anticoagulant therapies. Br J Anaesth 2002, 88:848-863.
24. Tiozzo R., Reggiani D., Cingi M.R., Bianchini P., Osima B., Calandra S. Effect of heparin derived fractions on the proliferation and protein synthesis of cells in culture. Thromb Res 1991, 62:177-188.
25. Yoneda M., Yamagata M., Suzuki S., Kimata K. Hyaluronic acid modulates proliferation of mouse dermal fibroblasts in culture. JCell Sci 1988, 90(Pt 2):265-273.
26. Koch C., Reck K., Shao K., Lin Q., Joussen S., Ziegler P., et al. Pluripotent stem cells escape from senescence-associated DNA methylation changes. Genome Res 2013, 23:248-259.
27. Schellenberg A., Stiehl T., Horn P., Joussen S., Pallua N., Ho A., et al. Population dynamics of mesenchymal stromal cells during culture expansion. Cytotherapy 2012, 14:401-411.
28. Schellenberg A., Hemeda H., Wagner W. Tracking of replicative senescence in mesenchymal stem cells by colony-forming unit frequency. Methods Mol Biol 2013, 976:143-154.
29. Marques-Gallego P., den D.H., Backendorf C., Brouwer J., Reedijk J., Burke J.F. Accurate non-invasive image-based cytotoxicity assays for cultured cells. BMC Biotechnol 2010, 10:43.
30. Papathanasopoulos A., Kouroupis D., Henshaw K., McGonagle D., Jones E.A., Giannoudis P.V. Effects of antithrombotic drugs fondaparinux and tinzaparin on in vitro proliferation and osteogenic and chondrogenic differentiation of bone-derived mesenchymal stem cells. JOrthop Res 2011, 29:1327-1335.
31. Ho A.D., Wagner W., Franke W. Heterogeneity of mesenchymal stromal cell preparations. Cytotherapy 2008, 10:320-330.
32. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317.
33. Schallmoser K., Rohde E., Reinisch A., Bartmann C., Thaler D., Drexler C., et al. Rapid large-scale expansion of functional mesenchymal stem cells from unmanipulated bone marrow without animal serum. Tissue Eng Part C Methods 2008, 14:185-196.
34. Schallmoser K., Strunk D. Generation of a pool of human platelet lysate and efficient use in cell culture. Methods Mol Biol 2013, 946:349-362.
35. Matziolis G., Perka C., Disch A., Zippel H. Effects of fondaparinux compared with dalteparin, enoxaparin and unfractionated heparin on human osteoblasts. Calcif Tissue Int 2003, 73:370-379.
36. Hausser H.J., Brenner R.E. Low doses and high doses of heparin have different effects on osteoblast-like Saos-2 cells in vitro. JCell Biochem 2004, 91:1062-1073.
37. Spivak-Kroizman T., Lemmon M.A., Dikic I., Ladbury J.E., Pinchasi D., Huang J., et al. Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation, and cell proliferation. Cell 1994, 79:1015-1024.
38. Handschin A.E., Trentz O.A., Hoerstrup S.P., Kock H.J., Wanner G.A., Trentz O. Effect of low molecular weight heparin (dalteparin) and fondaparinux (Arixtra) on human osteoblasts in vitro. Br J Surg 2005, 92:177-183.
39. Rajgopal R., Bear M., Butcher M.K., Shaughnessy S.G. The effects of heparin and low molecular weight heparins on bone. Thromb Res 2008, 122:293-298.
40. Muir J.M., Hirsh J., Weitz J.I., Andrew M., Young E., Shaughnessy S.G. Ahistomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats. Blood 1997, 89:3236-3242.
41. Sivakumaran M., Ghosh K., Zaidi Y., Hutchinson R.M. Osteoporosis and vertebral collapse following low-dose, low molecular weight heparin therapy in a young patient. Clin Lab Haematol 1996, 18:55-57.
42. Folwarczna J., Sliwinski L., Janiec W., Pikul M. Effects of standard heparin and low-molecular-weight heparins on the formation of murine osteoclasts in vitro. Pharmacol Rep 2005, 57:635-645.
43. Luo W., Shitaye H., Friedman M., Bennett C.N., Miller J., Macdougald O.A., et al. Disruption of cell-matrix interactions by heparin enhances mesenchymal progenitor adipocyte differentiation. Exp Cell Res 2008, 314:3382-3391.
44. Mathews S., Mathew S.A., Gupta P.K., Bhonde R., Totey S. Glycosaminoglycans enhance osteoblast differentiation of bone marrow derived human mesenchymal stem cells. JTissue Eng Regen Med 2012 Apr 12, [Epub ahead of print]. 10.1002/term.1507.
45. Eriksson B.I., Borris L.C., Friedman R.J., Haas S., Huisman M.V., Kakkar A.K., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. NEngl J Med 2008, 358:2765-2775.
46. Di N.M., Middeldorp S., Buller H.R. Direct thrombin inhibitors. NEngl J Med 2005, 353:1028-1040.
47. Bonin M., Stolzel F., Goedecke A., Richter K., Wuschek N., Holig K., et al. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant 2009, 43:245-251.
48. Osip S.L., Butcher M., Young E., Yang L., Shaughnessy S.G. Differential effects of heparin and low molecular weight heparin on osteoblastogenesis and adipogenesis in vitro. Thromb Haemost 2004, 92:803-810.